Clinical Trial Update: Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety, pharmacokinetics and pharmacodynamics of TKI258 (dovitinib) in subjects with acute myeloid leukemia, which was terminated…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• Dovitinib (dovitinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Myeloid Leukemia | Phase 1 | Status: TERMINATED